Answers are grounded in this paper and cite their sources.
Demonstrates that a biodegradable vagus nerve stimulator reduces plaque burden in atherosclerosis models, suggesting potential for cardiovascular therapies.
Bioelectronic modulation of the vagus nerve offers a promising strategy for treating cardiovascular disease. Murine models that recapitulate neuroimmune-metabolic dysregulation are indispensable for preclinical neuromodulation research; however, the murine vagus nerve is extremely small, fragile, and difficult to interface with, making it challenging for existing devices to achieve the miniaturization, performance, and chronic biocompatibility required for long-term studies. Herein, we present a miniaturized, focused-ultrasound-driven, fully biodegradable vagus-nerve stimulator (UBVS) specifically engineered for murine application, enabling reliable and safe wireless neuromodulation. UBVS integrates a fully biodegradable triboelectric energy harvester and a self-adherent neural interface, achieving stable, suture-free chronic coupling without local neural injury. On-demand focused ultrasound provides spatiotemporally controlled, transcutaneous wireless power to the UBVS, allowing for precise stimulation of the cervical vagus nerve located in deep tissue. In a murine atherosclerosis model, chronic UBVS-mediated vagus nerve stimulation reprogrammed the neuroimmune-metabolic axis by suppressing inflammatory activation, enhancing autophagy-efferocytosis and remodeling lipid metabolism, thereby reducing plaque burden. These innovations achieve neurocompatible, long-term stimulation of delicate peripheral nerves, advancing wireless electroceutical therapies for cardiovascular and other chronic diseases.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: